Cayman Chemical Company Incorporated

Aerie Pharmaceuticals, Inc.

Myometrics LLC

Andriy Kornilov

Stephen Douglas Barrett

Adam Uzieblo

Gregory William Endres

Bradlee David Germain

James Bernard Kramer

Joseph Michael Colombo

Fred Lawrence Ciske

Kirk M Maxey

Mitchell Anthony deLong

Jill Marie Sturdivant

Cynthia L Lichorowic

Thomas Allen Owen

James Paul O'Malley

Gilles Chambournier

Nancy Sue Barta

Hussein Mahmoud Mahmoud

Ivan Vesely

James Paul O'malley

Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents. In particular, these compounds are useful in the treatment of eye diseases such as glaucoma and retinal diseases, as anti-inflammatory agents, for the treatment of cardiovascular diseases, and for diseases characterized by abnormal growth, such as cancers.

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R, R, R, R, and Lare as defined herein. Compounds of formula (IA) have been found useful as EPreceptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders. 

Methods of synthesizing a difluorolactam analog

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Methods, systems, and compositions for promoting bone growth

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, R, R, R, and Rare as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

Growing community of inventors

Ypsilanti, MI, United States of America

Andriy Kornilov